Surveillance, Diagnosis, and Treatment Outcomes of Hepatocellular Carcinoma in Japan: 2021 Update.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed.

1. Laparoscopic hepatectomy is feasible for patients diagnosed with hepatocellular carcinoma and cirrhotic liver.World journal of gastrointestinal surgery · 2026
   Article
2. Hepatic Arterial Infusion Chemotherapy in the Treatment of Unresectable Hepatocellular Carcinoma with and Without Extrahepatic Spread: A Propensity Score Matching Study.Journal of personalized medicine · 2025
   Article
3. Complete Response After One Cycle of Atezolizumab Plus Bevacizumab in Advanced Hepatocellular Carcinoma: Two High-Risk Contexts, Child-Pugh Class B and Advanced Age.Cureus · 2025
   Article
4. Outcome and Prognosis of Invasive Treatment for Hepatocellular Carcinoma in Very Elderly Patients Over 90 Years Old.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025
   Article
5. The Impact of Sequential Therapies after First-Line Systemic Therapies in Unresectable Hepatocellular Carcinoma.Journal of clinical medicine · 2024
   Article
6. Comparative study on the efficacy and safety of transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for large unresectable hepatocellular carcinoma.Journal of gastrointestinal oncology · 2024
   Article
7. Current Therapeutic Strategies for Hepatocellular Carcinoma in Japan.Liver cancer · 2023
   Article
8. Survival Improvements in Advanced Hepatocellular Carcinoma with Sequential Therapy by Era.Cancers · 2023
   Article
9. Surveillance, Diagnosis, and Treatment Outcome of Hepatocellular Carcinoma in Japan: 2023 Update.Liver cancer · 2023
   Article
10. The prognosis of elderly patients with hepatocellular carcinoma: A multi-center 19-year experience in Japan.Cancer medicine · 2023
    Article
11. Management of hepatocellular carcinoma in patients who are 70 years or older.Surgery open science · 2022
    Article
12. Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis.Cancer medicine · 2022
    Article
13. Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy.Liver cancer · 2022
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as